Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) in a report published on Thursday,Benzinga reports. The firm currently has a $11.00 target price on the stock.

Several other analysts have also weighed in on the stock. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Finally, Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $9.40.

Recursion Pharmaceuticals Stock Down 0.1 %

NASDAQ RXRX traded down $0.01 on Thursday, hitting $6.96. 4,333,894 shares of the stock traded hands, compared to its average volume of 5,661,340. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a twelve month low of $5.03 and a twelve month high of $15.74. The stock has a 50-day moving average of $6.59 and a 200 day moving average of $7.63. The company has a market capitalization of $1.96 billion, a P/E ratio of -4.30 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the firm earned ($0.43) EPS. The business's revenue for the quarter was up 147.6% on a year-over-year basis. As a group, analysts expect that Recursion Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64. Following the completion of the sale, the director now directly owns 7,132,769 shares in the company, valued at approximately $50,785,315.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64. Following the transaction, the director now directly owns 7,132,769 shares in the company, valued at approximately $50,785,315.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company's stock, valued at approximately $3,288,380.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,682 shares of company stock worth $1,107,868 in the last three months. 15.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently bought and sold shares of RXRX. Janney Montgomery Scott LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $310,000. Capstone Investment Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter valued at about $161,000. Swiss National Bank boosted its holdings in Recursion Pharmaceuticals by 9.6% in the first quarter. Swiss National Bank now owns 308,500 shares of the company's stock valued at $3,076,000 after purchasing an additional 27,100 shares in the last quarter. Russell Investments Group Ltd. increased its position in Recursion Pharmaceuticals by 45.2% during the 1st quarter. Russell Investments Group Ltd. now owns 158,305 shares of the company's stock worth $1,578,000 after purchasing an additional 49,292 shares during the period. Finally, ProShare Advisors LLC boosted its position in Recursion Pharmaceuticals by 14.1% during the first quarter. ProShare Advisors LLC now owns 40,949 shares of the company's stock worth $408,000 after acquiring an additional 5,051 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.